Elevated concentrations or enzymatic activity of VAP-1/SSAO have been observed in patients with tobacco use, atherosclerosis, hypertension, heart failure, aortic stenosis, coronary artery disease, and diabetes mellitus, potentially leading to enhanced conversion of methylamine and aminoacetone (64–71). This evidence concerns the gene AOC3 and heart failure.